StealthWatch 6.0 unveiled

Jeff Byers | | Health Exec | Cybersecurity
Networking security company Lancope has unveiled the next generation of its StealthWatch System, which leverages flow data to deliver end-to-end network visibility and greater forensic intelligence for industries, including healthcare.

StealthWatch 6.0 capabilities include:

  • Application performance monitoring via behavioral analysis and inspection of flow data;
  • Relational flow mapping to provide real-time, graphical views of network traffic;
  • Grouping of related hosts to analyze the traffic between them, detect anomalies and assess performance; and
  • Reporting capabilities enabling users to retrieve detailed information for management.

Beta testers included Concord Hospital, in Concord, N.H., which used StealthWatch 6.0 to identify network and application security issues, according to Lancope, based in Atlanta.

Jeff Byers

Related Content

FBI seeking extradition of Israeli prisoner accused of $500M in ransomware attacks
Data breach at chain of clinics impacts 450K patients
Nebraska becomes first state to sue Change Healthcare over data breach
Christmas ransomware exposed over 300K patient records to dark web
Cryo-frozen tissue manufacturer suffers cyberattack
First surgical device of its kind granted key FDA exemption

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.